Sooma Medical

A patient uses the tDCS therapy at home. [Image courtesy of Sooma Medical]Sooma Medical announced today that it raised €5 million ($5.5 million) to support its at-home brain stimulation technology.

Nordic early-stage investor, Voima Ventures, led the funding round. Singapore-based Verge HealthTech Fund and existing investor Stephen Industries also participated. The funding marks a new phase of growth for Sooma in its mission, the company said in a news release.

Helsinki, Finland-based Sooma develops a flexible and accessible treatment solution called transcranial direct current stimulation (tDCS). Using a portable neuromodulation device, tDCS delivers a mild electrical current to stimulate the brain. Sooma designed it to alleviate depression symptoms without the need for pharmaceuticals.

Sooma’s treatment targets the brain and relieves symptoms without causing systemic side effects associated with antidepressants. The prescription-only therapies can p…

The neuromodulation kit developed by Sooma. [Image courtesy of Sooma Medical]Sooma Medical today announced that it received FDA breakthrough device designation for its neuromodulation device for treating depression.

The portable, patient-administered neuromodulation device utilizes a mild electrical current. It stimulates targeted brain areas resulting in a significant improvement in depressive symptoms.

“We are thrilled to receive this breakthrough designation from the FDA,” said Tuomas Neuvonen, Sooma CEO. “This designation recognizes that our device is a perfect solution, enabling a fast, effective and affordable treatment on a greater scale.

Neuvonen added that the company aims to make the treatment accessible to patients in U.S. “as quickly as possible.”

Sooma said its depression therapy offers a flexible treatment option with accessibility and affordability. It could benefit those underserved by medication or with limited access to …